InterCure Ltd. Price, Forecast, Insider, Ratings, Fundamentals & Signals

New york & herzliya, israel--(business wire)---- $incr #cannabis--intercure ltd. (nasdaq: incr) (tase: incr) (dba canndoc) ("intercure" or the "company"), the leading medical cannabis company outside of north america, is thrilled to congratulate the federal republic of germany for the passing of the “canng” cannabis act, which is expected to take effect on april 1, 2024. on the backdrop of this monumental development, intercure expects to launch a series of products in germany in the coming months. while the canna.

London--(business wire)---- $incr #canng--the pesg research has released an industry update following the regulatory shifts in germany. germany is expected to pass the cannabis act today (friday), heralding a transformative era for the medical cannabis industry. this legislative milestone, by removing cannabis from the 'narcotics act', is set to significantly ease the prescription process for medical cannabis, heralding profound implications for medical professionals, patients, and companies operating within th.

New york, and herzliya, israel, feb. 13, 2024 (globe newswire) -- intercure ltd. (nasdaq: incr) (tase: incr) (dba canndoc) ("intercure" or the "compan y"), the leading medical cannabis company in israel and outside of north america, reports today that, further to the company's press release issued on october 17, 2023, in which the company provided an update regarding the status of the security situation in israel, and its impact on the company and its employees, the company is providing an additional update regarding the status of its facility in kibbutz nir oz (the “southern israel site”).

New york, and herzliya, israel, jan. 31, 2024 (globe newswire) -- intercure ltd. (nasdaq: incr) (tase: incr) (dba canndoc) ("intercure" or the "compan y"), the leading medical cannabis company in israel and outside of north america, announced today that it has entered into a share purchase agreement (the “agreement”) with the shareholders of leon pharm ltd. (the “sellers”, and “leon pharm ”, respectively) to purchase leon pharm, a leading, israel-based pharmacy chain specializing in dispensing medical cannabis in israel, by way of a share purchase of all of the issued and outstanding share capital of leon pharm (the “transaction”).

New york and herzliya, israel , oct. 31, 2023 (globe newswire) -- intercure ltd. (nasdaq: incr) (tase: incr) (dba canndoc) ("intercure" or the "compan y"), the leading medical cannabis company in israel and outside of north america, reports today that, further to the company's press release issued on august 31, 2023, in which the company reported that the tel aviv-jaffa district court dismissed the lawsuit that filed against the company by minority shareholders of its subsidiary, cannolam ltd. (“cannolam”), and the parties agreed on a binding arbitration process (the “arbitration”), in which the amount owed to the company and the parties will be determined and paid as part of a full separation process, the company hereby reports that the arbitration has been concluded, and the arbitrator has decided in favor of the company on most of the claims presented to him by the company, while rejecting almost all of the claims presented by the minority shareholders.

InterCure Ltd. has faced challenges due to the conflict with Hamas, including not having access to a prime facility in Israel, but is expected to recover. The cannabis market in Israel is still limited to medical use, with expansion to medical cannabis patient access to grow the market in 2024. InterCure stock is cheap at only about 1x sales, with catalysts for growth in 2024 and beyond.

InterCure Ltd. (NASDAQ:INCR ) Q4 2022 Earnings Conference Call April 4, 2023 4:30 PM ET Company Participants Alexander Rabinovitch - CEO & Director Amos Cohen - CFO Conference Call Participants Vivien Azer - Cowen and Company Matt Bottomley - Canaccord Genuity Pablo Zuanic - Zuanic & Associates Operator Thank you for standing by, and welcome to InterCure's Fourth Quarter 2022 Earnings Call.

NEW YORK, TORONTO, and HERZLIYA, Israel, April 03, 2023 (GLOBE NEWSWIRE) -- InterCure Ltd . (NASDAQ: INCR) (TSX: INCR.U) (TASE: INCR) (dba Canndoc)("InterCure" or the “Company”) announced today that it has rescheduled its previously announced conference call to discuss the company's financial results for the full year ended December 31, 2022.

InterCure earned CAD$39 million in Q3 2022, up 61.2% from the previous year. Moreover, at the end of Q4 2022, the total number of licensed patients using cannabis for medical purposes in Israel was 123,212, up 13,860 from the previous year.

Negative conditions are crashing down all around investors. Make sure companies in your portfolio will survive.

Legal cannabis around the world is just beginning but will surpass that of North America. Europe is one of the largest growth markets for companies in global cannabis.

InterCure is the leading cannabis operator in Israel. Israel is currently a medical market, with recreational legalization expected to occur over the coming years.

The global cannabis market will eventually be far bigger than North America. InterCure is a leading company in global pharmaceutical cannabis.

InterCure Ltd (NASDAQ:INCR ) Q2 2022 Earnings Conference Call August 16, 2022 8:30 AM ET Company Participants Adam Haliva - Communications Officer Alexander Rabinovitch - CEO & Director Amos Cohen - CFO Conference Call Participants Victor Ma - Cowen and Company Pablo Zuanic - Cantor Fitzgerald Yewon Kang - Canaccord Genuity Operator Good day, and thank you for standing by. Welcome to the InterCure Second Quarter 2022 Earnings Call and Webcast.

Welcome back to our weekly series, Schaeffer's Cannabis Stock News Update, where we recap what happened in the world of marijuana stocks this week, and look ahead to how the cannabis industry will continue to develop in 2022.